Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-cash Items (2016 - 2022)

Spyre Therapeutics' Non-cash Items history spans 8 years, with the latest figure at $2000.0 for Q4 2022.

  • For Q4 2022, Non-cash Items fell 99.39% year-over-year to $2000.0; the TTM value through Dec 2022 reached $2000.0, down 99.39%, while the annual FY2022 figure was $2000.0, 100.0% down from the prior year.
  • Non-cash Items reached $2000.0 in Q4 2022 per SYRE's latest filing, down from $328000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $4.8 million in Q4 2018 to a low of $2000.0 in Q4 2022.
  • Average Non-cash Items over 5 years is $2.5 million, with a median of $3.6 million recorded in 2019.
  • Peak YoY movement for Non-cash Items: surged 93.31% in 2018, then plummeted 99.39% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $4.8 million in 2018, then fell by 24.09% to $3.6 million in 2019, then grew by 4.01% to $3.8 million in 2020, then tumbled by 91.34% to $328000.0 in 2021, then tumbled by 99.39% to $2000.0 in 2022.
  • Per Business Quant, the three most recent readings for SYRE's Non-cash Items are $2000.0 (Q4 2022), $328000.0 (Q4 2021), and $3.8 million (Q4 2020).